Julie Ho1,2, Stefan Schaub3, Chris Wiebe1, Ang Gao2, Caroline Wehmeier3, Michael T Koller3,4, Hans H Hirsch5,6, Helmut Hopfer7, Peter Nickerson1,2,8, Patricia Hirt-Minkowski3. 1. Transplantation and Nephrology, University of Manitoba, Winnipeg, Manitoba, Canada. 2. Manitoba Centre for Proteomics and Systems Biology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. 3. Transplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland. 4. Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland. 5. Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland. 6. Transplantation and Clinical Virology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland. 7. Institute for Pathology, University Hospital Basel, Basel, Switzerland. 8. Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada.
Abstract
BACKGROUND: Urinary CXC chemokine ligand 10 (CXCL10) is a promising biomarker for subclinical tubulointerstitial inflammation, but limited data exist regarding its correlation with (micro)vascular inflammation. Furthermore, no study has evaluated whether concomitant serum CXCL10 improves the discrimination for (micro)vascular inflammation. METHODS: We investigated whether serum/urinary CXCL10 reflect subclinical inflammation within different renal compartments. Patients (n = 107) with 107 surveillance biopsies were classified as: normal histology (n = 47), normal histology with polyomavirus BK (BKV) or cytomegalovirus (CMV) viremia (n = 17), moderate-severe tubulointerstitial inflammation (tubulitis ≥2, n = 18), pure microvascular inflammation (n = 15), and isolated v lesions (n = 10). Serum and urinary CXCL10 Enzyme-linked Immunosorbent Assay was performed. An independent validation set was evaluated for urine CXCL10: normal histology (n = 14), normal histology with BKV or CMV viremia (n = 19), tubulitis ≥2 (n = 15), pure microvascular inflammation (n = 41), and isolated v lesions (n = 14). RESULTS: Elevated urinary CXCL10 reflected inflammation within the tubulointerstitial (urinary CXCL10/creatinine, 1.23 ng/mmol vs 0.46 ng/mmol; P = 0.02; area under the curve, 0.69; P = 0.001) and microvascular compartments (urinary CXCL10/creatinine, 1.72 ng/mmol vs 0.46 ng/mmol; P = 0.03; area under the curve, 0.69; P = 0.02) compared to normal histology. Intriguingly, urinary CXCL10 was predominantly elevated with peritubular capillaritis, but not glomerulitis (P = 0.04). Furthermore, urinary CXCL10 corresponded with BKV, but not CMV viremia (P = 0.02). These urine CXCL10 findings were confirmed in the independent validation set. Finally, serum CXCL10 was elevated with BKV and CMV viremia but was not associated with microvascular or vascular inflammation (P ≥ 0.19). CONCLUSIONS: Urinary CXCL10 reflects subclinical inflammation within the tubulointerstitial and peritubular capillary spaces, but not the vascular/systemic compartments; this was consistent with BKV (tubulointerstitial) and CMV viremia (systemic). Serum CXCL10 was not a useful marker for (micro)vascular inflammation.
BACKGROUND: Urinary CXC chemokine ligand 10 (CXCL10) is a promising biomarker for subclinical tubulointerstitial inflammation, but limited data exist regarding its correlation with (micro)vascular inflammation. Furthermore, no study has evaluated whether concomitant serum CXCL10 improves the discrimination for (micro)vascular inflammation. METHODS: We investigated whether serum/urinary CXCL10 reflect subclinical inflammation within different renal compartments. Patients (n = 107) with 107 surveillance biopsies were classified as: normal histology (n = 47), normal histology with polyomavirus BK (BKV) or cytomegalovirus (CMV) viremia (n = 17), moderate-severe tubulointerstitial inflammation (tubulitis ≥2, n = 18), pure microvascular inflammation (n = 15), and isolated v lesions (n = 10). Serum and urinary CXCL10 Enzyme-linked Immunosorbent Assay was performed. An independent validation set was evaluated for urine CXCL10: normal histology (n = 14), normal histology with BKV or CMV viremia (n = 19), tubulitis ≥2 (n = 15), pure microvascular inflammation (n = 41), and isolated v lesions (n = 14). RESULTS: Elevated urinary CXCL10 reflected inflammation within the tubulointerstitial (urinary CXCL10/creatinine, 1.23 ng/mmol vs 0.46 ng/mmol; P = 0.02; area under the curve, 0.69; P = 0.001) and microvascular compartments (urinary CXCL10/creatinine, 1.72 ng/mmol vs 0.46 ng/mmol; P = 0.03; area under the curve, 0.69; P = 0.02) compared to normal histology. Intriguingly, urinary CXCL10 was predominantly elevated with peritubular capillaritis, but not glomerulitis (P = 0.04). Furthermore, urinary CXCL10 corresponded with BKV, but not CMV viremia (P = 0.02). These urine CXCL10 findings were confirmed in the independent validation set. Finally, serum CXCL10 was elevated with BKV and CMV viremia but was not associated with microvascular or vascular inflammation (P ≥ 0.19). CONCLUSIONS: Urinary CXCL10 reflects subclinical inflammation within the tubulointerstitial and peritubular capillary spaces, but not the vascular/systemic compartments; this was consistent with BKV (tubulointerstitial) and CMV viremia (systemic). Serum CXCL10 was not a useful marker for (micro)vascular inflammation.
Authors: Lukas Weseslindtner; Lea Hedman; Yilin Wang; Robert Strassl; Ilkka Helanterä; Stephan W Aberle; Gregor Bond; Klaus Hedman Journal: Transpl Int Date: 2020-02-13 Impact factor: 3.782
Authors: Ping An; Maria Teresa Sáenz Robles; Alexis M Duray; Paul G Cantalupo; James M Pipas Journal: PLoS Pathog Date: 2019-01-08 Impact factor: 6.823
Authors: Julie Ho; Atul Sharma; Kristine Kroeker; Robert Carroll; Sacha De Serres; Ian W Gibson; Patricia Hirt-Minkowski; Anthony Jevnikar; S Joseph Kim; Greg Knoll; David N Rush; Chris Wiebe; Peter Nickerson Journal: BMJ Open Date: 2019-04-11 Impact factor: 2.692
Authors: Thiago J Borges; Phammela Abarzua; Rodrigo B Gassen; Branislav Kollar; Mauricio Lima-Filho; Bruno T Aoyama; Diana Gluhova; Rachael A Clark; Sabina A Islam; Bohdan Pomahac; George F Murphy; Christine G Lian; Simon G Talbot; Leonardo V Riella Journal: Cell Rep Med Date: 2022-03-15